ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cellect Biotechnology Receives Approval for U.S. Clinical Trial
December 24, 2019Cellect Biotechnology has received approval to initiate the trial in the U.S. to evaluate the safety and tolerability of the ApoGraft technology for haploidentical bone marrow transplantations. -
FDA Grants Orphan Drug Status to ApoGraft for Acute and Chronic GvHD
September 06, 2017Cellect Biotechnology announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cellect's ApoGraft for the prevention of acute and chronic graft versus host disease (GvHD) in transplant patients. -
FDA grants orphan drug status to Cellect’s ApoGraft
September 06, 2017The FDA has granted orphan drug designation for ApoGraft for the prevention of acute and chronic graft versus host disease…
Pharma Sources Insight January 2025
